Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities

BACKGROUND: Lefamulin, a first-in-class pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia (CABP), was noninferior to moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) 1 intravenous-to-oral switch study and the LEAP 2...

Descripción completa

Detalles Bibliográficos
Autores principales: File, Thomas M., Alexander, Elizabeth, Goldberg, Lisa, Das, Anita F., Sandrock, Christian, Paukner, Susanne, Moran, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105923/
https://www.ncbi.nlm.nih.gov/pubmed/33964925
http://dx.doi.org/10.1186/s12890-021-01472-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105923/
https://www.ncbi.nlm.nih.gov/pubmed/33964925
http://dx.doi.org/10.1186/s12890-021-01472-z

Ejemplares similares